Carcinoma, Neuroendocrine
-
Subject Areas on Research
-
A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.
-
A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer.
-
ASO Author Reflection: Postoperative Chemotherapy for Nonmetastatic, Poorly Differentiated Gastroenteropancreatic Neuroendocrine Carcinomas.
-
Adjuvant Chemotherapy Versus Observation Following Resection for Patients With Nonmetastatic Poorly Differentiated Colorectal Neuroendocrine Carcinomas.
-
Adjuvant Therapy for Patients With Early Large Cell Lung Neuroendocrine Cancer: A National Analysis.
-
Aggressive variants of castration-resistant prostate cancer.
-
Altered telomeres in tumors with ATRX and DAXX mutations.
-
Alternative Splicing Provides a Novel Molecular Mechanism for Prostatic Small-cell Neuroendocrine Carcinoma.
-
CD44 expression is a feature of prostatic small cell carcinoma and distinguishes it from its mimickers.
-
Changes in Serum Calcitonin Concentrations, Incidence of Medullary Thyroid Carcinoma, and Impact of Routine Calcitonin Concentration Monitoring in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL).
-
Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study.
-
Clonality of combined tumors.
-
Cystic pancreatic neuroendocrine tumors: a clinicopathologic study.
-
Differential expression of interleukin-8 and its receptors in the neuroendocrine and non-neuroendocrine compartments of prostate cancer.
-
Donor-Derived Neuroendocrine Carcinoma Transmission to Two Kidney Transplant Recipients Demonstrated by Short Tandem Repeat Analysis: A Case Report.
-
Down-regulation of ADRB2 expression is associated with small cell neuroendocrine prostate cancer and adverse clinical outcomes in castration-resistant prostate cancer.
-
Evolving application of minimally invasive cancer operations at a tertiary cancer center.
-
Expression of PD-1 and PD-L1 in poorly differentiated neuroendocrine carcinomas of the digestive system: a potential target for anti-PD-1/PD-L1 therapy.
-
FOXA2 is a sensitive and specific marker for small cell neuroendocrine carcinoma of the prostate.
-
Hedgehog signaling in human medullary thyroid carcinoma: a novel signaling pathway.
-
High-grade neuroendocrine carcinomas of the lung highly express enhancer of zeste homolog 2, but carcinoids do not.
-
Hyaline globules in neuroendocrine and solid-pseudopapillary neoplasms of the pancreas: a clue to the diagnosis.
-
Impact of Postoperative Chemotherapy on the Survival of Patients with High-Grade Gastroenteropancreatic Neuroendocrine Carcinoma.
-
Liver Mass: Thinking Out of the Box.
-
MEN1 gene mutation analysis of high-grade neuroendocrine lung carcinoma.
-
Major vascular resection as part of pancreaticoduodenectomy for cancer: radiologic, intraoperative, and pathologic analysis.
-
N-Myc promotes therapeutic resistance development of neuroendocrine prostate cancer by differentially regulating miR-421/ATM pathway.
-
Nerve growth factor interacts with CHRM4 and promotes neuroendocrine differentiation of prostate cancer and castration resistance.
-
Neuroendocrine carcinomas of the gallbladder: Lessons learnt from cases at opposite ends of the spectrum.
-
Neuroendocrine differentiation of prostate cancer.
-
Neuroendocrine lung tumors and disorders of the neuromuscular junction.
-
Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes.
-
Outcomes for Surgery in Large Cell Lung Neuroendocrine Cancer.
-
PC3 is a cell line characteristic of prostatic small cell carcinoma.
-
Platinum-Based Treatment for Well- and Poorly Differentiated Pancreatic Neuroendocrine Neoplasms.
-
Poorly differentiated neuroendocrine carcinomas of the pancreas: a clinicopathologic analysis of 44 cases.
-
Primary Breast Neuroendocrine Tumor.
-
Primary hepatic neoplasms arising in cirrhotic livers can have a variable spectrum of neuroendocrine differentiation.
-
Primary high-grade neuroendocrine carcinoma emerging from an adenomatous polyp in the setting of familial adenomatous polyposis.
-
Primary high-grade neuroendocrine carcinoma of the esophagus: a clinicopathologic and immunohistochemical study of 42 resection cases.
-
Primary tumor resection improves survival of gastrointestinal neuroendocrine carcinoma patients with nonresected liver metastases.
-
Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage.
-
Rethinking the Current American Joint Committee on Cancer TNM Staging System for Medullary Thyroid Cancer.
-
Roles of Alternative RNA Splicing of the Bif-1 Gene by SRRM4 During the Development of Treatment-induced Neuroendocrine Prostate Cancer.
-
Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study.
-
Single nucleotide polymorphisms act as modifiers and correlate with the development of medullary and simultaneous medullary/papillary thyroid carcinomas in 2 large, non-related families with the RET V804M proto-oncogene mutation.
-
Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors.
-
Staging of esophageal cancer by EUS: staging accuracy revisited.
-
Surgical management of medullary thyroid carcinoma.
-
Survival outcomes in sinonasal carcinoma with neuroendocrine differentiation: A NCDB analysis.
-
Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer.
-
TP53, CDKN2A/P16, and NFE2L2/NRF2 regulate the incidence of pure- and combined-small cell lung cancer in mice.
-
Targeting Protein Arginine Methyltransferase 5 Suppresses Radiation-induced Neuroendocrine Differentiation and Sensitizes Prostate Cancer Cells to Radiation.
-
Targeting RET Kinase in Neuroendocrine Prostate Cancer.
-
The Role of CD44 in Glucose Metabolism in Prostatic Small Cell Neuroendocrine Carcinoma.
-
Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
-
Treatment Response and Outcomes of Grade 3 Pancreatic Neuroendocrine Neoplasms Based on Morphology: Well Differentiated Versus Poorly Differentiated.
-
Treatment of High-Grade Metastatic Pancreatic Neuroendocrine Carcinoma with FOLFIRINOX.
-
Use of Dexmedetomidine in a Parturient With Multiple Endocrine Neoplasia Type 2A Undergoing Adrenalectomy and Thyroidectomy: A Case Report.
-
[Neuroendocrine differentiation in prostate cancer].
-
p53 Mutation Directs AURKA Overexpression via miR-25 and FBXW7 in Prostatic Small Cell Neuroendocrine Carcinoma.
-
Keywords of People